Globus Medical, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-53.3% vs price
Base Case (Median)
-36.1% vs price
Bull Case (75th pct.)
16.1% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $18.94 | -77.7% | High (40%) |
| PE Comparable | $86.57 | 1.7% | Medium (25%) |
| Growth Trajectory DCF | $155.35 | 82.5% | Medium (20%) |
| Graham Number | $54.42 | -36.1% | Medium (40%) |
| EV/EBITDA | $54.01 | -36.6% | Medium (20%) |
| EV/FCF | $111.07 | 30.5% | Medium (20%) |
| Earnings Power Value | $25.47 | -70.1% | Medium (50%) |
Based on 7 out of 8 methods, GMED appears fairly valued at the current price of $85.12. The base case fair value of $54.42 implies 36.1% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.